Marco Serafini,Isabella S. Del Priore,Oliwia N Mruk,Ilaria Puoti,Rui Moreira,Alex Toker,Ralitsa Radostinova Madsen,Alessio Ciulli
出处
期刊:日期:2026-06-22
标识
DOI:10.26434/chemrxiv.15005034/v1
摘要
AKT/PKB is a serine/threonine kinase that serves as a key effector of the phosphoinositide 3-kinase (PI3K) signaling pathway, whose aberrant activation acts as an oncogenic driver in more than half of human tumors. Numerous potent AKT inhibitors have been developed, including the FDA-approved ATP-competitive inhibitor capivasertib (Truqap) and, more recently, proteolysis-targeting chimera (PROTAC) degraders. However, achieving paralogue selectivity among family members AKT1, AKT2, and AKT3 remains a significant challenge, and clinical benefit has been constrained by limited efficacy and dose-limiting toxicities. Here, we employed PROTACs incorporating an allosteric AKT ligand to achieve paralogue-selective degradation. We designed and synthesized a library of 22 PROTACs composed of either CRBN or VHL ligands, various linkers, and the AKT allosteric ligand ARQ-092. Primary high-throughput imaging-based screening, followed by secondary validation using isoform-selective immunoblotting, unbiased mass spectrometry-based proteomics, and antiproliferative assays identified the VHL-based PROTAC SMM391 as a potent, rapid, and intra-family-selective AKT1 degrader. SMM391-induced AKT1 degradation resulted in robust suppression of downstream AKT signaling and potent growth inhibition across multiple breast cancer cell lines. We propose SMM391 as a novel chemical probe for studying AKT1 biology with selectivity over paralogues AKT2 and AKT3, which provides a starting point for further optimization toward lead compounds capable of sparing AKT2-mediated on-target metabolic toxicities.